Evidence map›Paper›PMID 30182156›Full record

SynthesisSocial psychiatry and psychiatric epidemiology2018

Mild cognitive impairment and progression to dementia in people with diabetes, prediabetes and metabolic syndrome: a systematic review and meta-analysis.

Kingshuk Pal, Naaheed Mukadam, Irene Petersen, Claudia Cooper

Registry-linked trialOpen access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Social psychiatry and psychiatric epidemiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06072963 (Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow), which is not on this map. Cited by 141 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed, 9 pooled it
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06072963 phase2recruitingstarted 2024, after this paper: background citation

Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study

Ran2024Enrolled80Registered outcomes15Posted comparisons0ConditionsAlzheimer Disease, Metabolic Syndrome, Mild Cognitive ImpairmentArmsIntranasal insulin, Intranasal insulin placebo, semaglutide, Semaglutide placebo
PMID 36871874PMID 29687620PMID 34039508PMID 34101779PMID 34305810PMID 34636161PMID 34756135PMID 35079029PMID 35482079PMID 3662782PMID 8563978PMID 9191756other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

141 citing papers in PubMed, 9 syntheses or guidelines pooled it, 283 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

81 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Kingshuk PalResearch Department of Primary Care and Population Health, UCL, London, UK. k.pal@ucl.ac.uk.ORCID http://orcid.org/0000-0001-6630-6684
Naaheed MukadamDivision of Psychiatry, Faculty of Brain Sciences, UCL, London, UK.
Irene PetersenResearch Department of Primary Care and Population Health, UCL, London, UK.
Claudia CooperDivision of Psychiatry, Faculty of Brain Sciences, UCL, London, UK.
University College London · GBDepartment of Health and Social Care · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe aimed to quantify the relative risk of progression from mild cognitive impairment (MCI) to dementia in people with and without diabetes, and with and without the MetS (MetS); and to identify potential modifiers of the risk of progression from MCI to dementia in people with diabetes or MetS.

methodsWe searched Medline, Embase, PsycINFO, PsycArticles and Web of Science from inception through to 20th March 2018. Where possible, the results from three or more studies were pooled in a meta-analysis, while other findings have been described narratively.

resultsWe included 15 articles reporting 12 studies (6865 participants). The overall unadjusted pooled odds ratio for the progression of MCI to dementia in people with diabetes/MetS was 1.67 (95% CI 1.27-2.19); the pooled odds ratio for progression in diabetes + MCI was 1.53 (95% CI 1.20-1.97) and in people with MetS + MCI was 2.95 (95% CI 1.23-7.05). There was moderate heterogeneity in the included studies (I

conclusionsDiabetes and MetS were both associated with an increased incidence of dementia when co-existing with MCI. Intensive cardiovascular risk reduction and lifestyle changes for patients presenting with MCI and diabetes, prediabetes or MetS may be important in reducing incidence of dementia in this high risk population.

Indexed as

ComorbidityDisease ProgressionCognitive DysfunctionDementiaDiabetes Mellitus, Type 2HumansMetabolic SyndromePrediabetic StateDementiaMCIMeta-analysisSystematic reviewT2D

Identifiers

PMID30182156
PMCPMC6208946
OpenAlexW2889843430

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.